Stock 688076 JIANGSU SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.

Equities

688076

CNE1000051X5

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 20/06/2024 BST 		5-day change 1st Jan Change
76.9 CNY +5.63% Intraday chart for Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. +25.24% +71.08%
05-21 Certain A Shares of Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-MAY-2024. CI
04-22 Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 8,811 4,890 9,583 16,394 - -
Enterprise Value (EV) 1 8,811 4,890 9,583 16,394 16,394 16,394
P/E ratio 68.9 x 37.6 x 59.1 x 60.2 x 41.5 x 30 x
Yield - - 0.89% 0.79% 1.23% 1.69%
Capitalization / Revenue 13.7 x 7.51 x 9.25 x 10.9 x 7.84 x 5.83 x
EV / Revenue 13.7 x 7.51 x 9.25 x 10.9 x 7.84 x 5.83 x
EV / EBITDA 41.1 x 21.4 x 29.4 x 33.5 x 24.2 x 18.2 x
EV / FCF - - - -34.3 x -45.3 x 49.8 x
FCF Yield - - - -2.92% -2.21% 2.01%
Price to Book 4.86 x 2.56 x 4.37 x 6.99 x 6.2 x 5.37 x
Nbr of stocks (in thousands) 213,184 213,184 213,184 213,184 - -
Reference price 2 41.33 22.94 44.95 76.90 76.90 76.90
Announcement Date 27/02/22 27/02/23 23/02/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 643.9 651.3 1,036 1,509 2,091 2,811
EBITDA 1 - 214.2 228.3 325.4 489.7 678.3 901
EBIT 1 - 128.3 124.9 189.1 309.8 453.8 631
Operating Margin - 19.93% 19.17% 18.26% 20.53% 21.7% 22.45%
Earnings before Tax (EBT) 1 - 125.7 123.2 170 311.3 454.3 634
Net income 1 123.4 115.4 129.1 161.3 271.5 394.2 545.8
Net margin - 17.92% 19.82% 15.58% 18% 18.85% 19.41%
EPS 2 0.7700 0.6000 0.6100 0.7600 1.278 1.855 2.562
Free Cash Flow 1 - - - - -478 -362 329
FCF margin - - - - -31.68% -17.31% 11.7%
FCF Conversion (EBITDA) - - - - - - 36.51%
FCF Conversion (Net income) - - - - - - 60.28%
Dividend per Share 2 - - - 0.4000 0.6050 0.9450 1.300
Announcement Date 25/04/21 27/02/22 27/02/23 23/02/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q2 2023 Q3
Net sales - -
EBITDA - -
EBIT - -
Operating Margin - -
Earnings before Tax (EBT) - -
Net income 1 20.84 49.86
Net margin - -
EPS 0.1000 -
Dividend per Share - -
Announcement Date 28/08/23 20/10/23
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - - - - -478 -362 329
ROE (net income / shareholders' equity) - 7.97% 6.94% 8.18% 11.5% 14.8% 17.6%
ROA (Net income/ Total Assets) - - - 5.29% 7.89% 10.2% 12.4%
Assets 1 - - - 3,050 3,441 3,863 4,414
Book Value Per Share 2 - 8.500 8.960 10.30 11.00 12.40 14.30
Cash Flow per Share 2 - 0.8500 0.1400 1.640 1.810 1.510 1.940
Capex 1 - 233 438 659 391 377 227
Capex / Sales - 36.19% 67.3% 63.64% 25.92% 18.04% 8.08%
Announcement Date 25/04/21 27/02/22 27/02/23 23/02/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
76.9 CNY
Average target price
62.24 CNY
Spread / Average Target
-19.06%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
JIANGSU SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD. Stock Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.
+71.08% 2.26B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.63% 796B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.51% 628B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.10% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.90% 331B
ABBVIE INC. Stock AbbVie Inc.
+9.95% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.66% 244B
ROCHE HOLDING AG Stock Roche Holding AG
+3.39% 228B
NOVARTIS AG Stock Novartis AG
+10.75% 214B
AMGEN INC. Stock Amgen Inc.
+6.99% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 688076 Stock
  4. Financials Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.